American Society of Hematology (ASH)

The American Society of Hematology (ASH) is a professional organization representing hematologists. It was founded in 1958. Its annual meeting is held in December of every year and has attracted more than 30,000 attendees. The society publishes the medical journal Blood, the most cited peer-reviewed publication in the field, which is available weekly in print and online, as well as the newly launched, online, peer-reviewed open-access journal, Blood Advances.
Compared with standard-of-care therapies delivered in a real-world setting, daratumumab monotherapy extends overall survival in patients with heavily pretreated and highly refractory multiple myeloma. Read More ›

Researchers conducted a systematic literature review and subsequent meta-analysis of progression-free survival outcomes to compare 16 different treatment regimens for relapsed/refractory multiple myeloma.

Read More ›

New treatment approaches are needed in multiple myeloma to extend relapse-free intervals and overall survival. In a phase 1/2 trial, the combination of pomalidomide, dexamethasone, and weekly carfilzomib showed impressive efficacy with acceptable tolerability.

Read More ›

This phase 2 study of elotuzumab, lenalidomide, and dexamethasone combination therapy in a high-risk population of patients with smoldering multiple myeloma showed promising efficacy and tolerability.

Read More ›

High response rates with the combination of elotuzumab (Empliciti), lenalidomide (Revlimid), and dexamethasone in the treatment of patients with high-risk smoldering multiple myeloma suggest that early intervention may be worthwhile in this patient population, based on results from a phase 2 study, said Irene M. Ghobrial, MD, Attending Physician, Medical Oncology, Dana-Farber Cancer Institute, Boston, at the 2016 American Society of Hematology meeting. Read More ›

Healthcare stakeholders have formulated a number of management approaches to ensure that patients receive appropriate therapies. Here, clinicians at Cleveland Clinic report on a response-adapted treatment protocol for newly diagnosed patients with multiple myeloma.

Read More ›

Investigational agents with novel mechanisms of action continue to show promise in treating multiple myeloma. In this study, researchers report findings of a phase 1a/1b study evaluating an oral HDAC6 inhibitor.

Read More ›

The majority of patients with smoldering multiple myeloma do not receive active treatment. In this study, treatment of a high-risk population with lenalidomide and dexamethasone yielded favorable patient outcomes.

Read More ›

Recent data showed that lenalidomide maintenance therapy is an effective option for both transplant-eligible and nontransplant-eligible patients with multiple myeloma.

Read More ›

As more patients receive maintenance therapy for multiple myeloma, researchers seek to evaluate the impact of toxicities associated with long-term treatment on health-related quality of life in these patient populations.

Read More ›

Page 30 of 44

Conference Coverage Proudly Presented by
CONQUER: the patient voice
Journal of Oncology Navigation & Survivorship
Oncology Practice Management
The Oncology Nurse–APN/PA
The Oncology Pharmacist
Value-Based Cancer Care

Learn more about our family of publications.

View Our Publications